SEC Form 4 · accession 0001209191-17-021686
Foundation Medicine, Inc. · FMI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Ryan
Officer — Chief Financial Officer
Period of report
Mar 16, 2017
Accepted (ET)
Mar 20, 2017 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001488613
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 16, 2017 | M | 3,250 | $0.84 | A | 56,230 | D | |
| Common Stock | Mar 16, 2017 | M | 9,250 | $4.16 | A | 65,480 | D | |
| Common StockF1 | Mar 16, 2017 | S | 12,500 | $31.68 | D | 52,980 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| stock option (right to buy)F2 | $0.84 | Mar 16, 2017 | M | 3,250 | D | — | Mar 27, 2022 | Common Stock | 3,250 | 0 | D |
| stock option (right to buy)F3 | $4.16 | Mar 16, 2017 | M | 9,250 | D | — | Mar 7, 2023 | Common Stock | 9,250 | 0 | D |
Explanation of responses
- F1The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.53 to $31.95, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- F2This option was granted on March 27, 2012 and vested in equal quarterly installments beginning on June 27, 2012 until fully vested on March 27, 2016.
- F3This option was granted on March 7, 2013 and vested in equal quarterly installments beginning on June 7, 2013 until fully vested on March 7, 2017.